RU, Общество с ограниченной ответственностью "Ленин-Сити-Т", 305000, г. Курск, ул. Ленина, д.12
Registrator
305035, г. Курск, ул. Дзержинского, д. --, кв. --, Шанцевой Елене Юрьевне
Classes
43
NICE Classification
кафе;
рестораны;
создание кулинарных скульптур;
украшение еды;
украшение тортов;
услуги по приготовлению блюд и доставке их на дом;
Domain names similar "SAVA"
News around "SAVA" trademark
News sentiment analysis powered by sentiment-insight.com
2023-07-29
positive
Top 12 Small-Cap Stocks With Highest Upside Potential
A small cap stock is defined as one whose market value sits between $300 million and $2 billion. Impinj, Inc. (NASDAQ:PI)'s biggest shareholder is Daniel Patrick Gibson's Sylebra Capital Management with an investment of $385 million. Ligand Pharmaceuticals Incorporated (NASdaq:LGND), Cassava Sciences, Inc (NASCAR:SAVA), and Piedmont Lithium Inc. are some top small stocks with high upside.
2023-06-12
negative
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Cassava Sciences (NASDAQ:SAVA) shareholders should be worried about its cash burn. Cash burn is the amount of money a company spends each year to fund its growth. Cassava Sciences' cash burn of US$70m is about 6.9% of its US$1.0b market capitalisation. It would probably be really easy for the company to fund another year's growth by issuing some new shares to investors.
2023-03-13
positive
Why Cassava Sciences Stock Is Surging After Hours - NewsBreak
Cassava Sciences Inc (NASDAQ: SAVA) shares are rising in extended trading Wednesday in the wake of recent insider buying.
2023-02-02
negative
MP Evans Group "fully expects" to continue growing in 2023
Cassava Sciences (NASDAQ: SAVA) is exploring whether its drug called simufilam is safe and effective to treat early-stage Alzheimer's disease. The market reacted quite negatively to the release of new data that management spun as being positive.
2023-02-01
negative
IIROC Trading Halt - XOP
Cassava Sciences (NASDAQ: SAVA) is likely to be near the top of the list. The biggest reason to sell Cassava stock: After an open-label phase 2 clinical trial of simufilam.
2023-01-09
positive
6 Favorite Biotech Bets For 2023
Cassava Sciences (SAVA) is a high risk, high reward clinical biotech company. Its flagship drug candidate is Simufilam — an Alzheimer’s drug. If it gets approved, it could easily become a multi-billion dollar drug.
Sign Up
